Island Pharmaceuticals Limited
Island Pharmaceuticals Limited (ILA.AX) Financial Performance & Income Statement Overview
Explore the financials of Island Pharmaceuticals Limited (ILA.AX), including yearly and quarterly data on income, cash flow, and balance sheets.
Island Pharmaceuticals Limited (ILA.AX) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Island Pharmaceuticals Limited ILA.AX financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $302524.00 | $474526.00 | $5533.00 | $5533.00 |
| Cost of Revenue | $991774.00 | $640397.00 | $0.00 | $0.00 |
| Gross Profit | -$689250.00 | -$165871.00 | $5533.00 | $5533.00 |
| Gross Profit Ratio | -$2.28 | -$0.35 | $1.00 | $1.00 |
| R&D Expenses | $991774.00 | $1.28M | $470405.00 | $235203.00 |
| SG&A Expenses | $1.002M | $850762.00 | $800402.00 | $400201.00 |
| Operating Expenses | $1.99M | $2.13M | $1.27M | $613086.00 |
| Total Costs & Expenses | $2.99M | $2.13M | $1.27M | $613086.00 |
| Interest Income | $1890.00 | $3769.00 | $6506.00 | $2279.00 |
| Interest Expense | $66694.00 | $12854.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.69M | $586253.00 | $629871.00 | $629871.00 |
| EBITDA | -$1.98M | -$1.53M | -$1.22M | -$5533.00 |
| EBITDA Ratio | -$6.54 | -$4.49 | -$229.68 | $3.62 |
| Operating Income | -$2.68M | -$2.13M | -$1.27M | -$629871.00 |
| Operating Income Ratio | -$8.87 | -$4.49 | -$229.68 | -$113.84 |
| Other Income/Expenses (Net) | -$1.34M | $590139.00 | $51144.00 | $20038.00 |
| Income Before Tax | -$4.02M | -$1.54M | -$1.22M | -$609833.00 |
| Income Before Tax Ratio | -$13.30 | -$3.25 | -$220.43 | -$110.22 |
| Income Tax Expense | -$2.31M | -$386345.00 | -$629871.00 | $20038.00 |
| Net Income | -$1.71M | -$1.16M | -$1.22M | -$609833.00 |
| Net Income Ratio | -$5.65 | -$2.43 | -$220.43 | -$110.22 |
| EPS | -$0.02 | -$0.01 | -$0.01 | -$0.007 |
| Diluted EPS | -$0.02 | -$0.01 | -$0.01 | -$0.007 |
| Weighted Avg Shares Outstanding | $99.33M | $87.52M | $87.52M | $81.28M |
| Weighted Avg Shares Outstanding (Diluted) | $99.32M | $87.52M | $87.52M | $81.27M |
Over the last four quarters, Island Pharmaceuticals Limited's revenue moved from $5533.00 in Q3 2023 to $302524.00 in Q4 2024. Operating income in Q4 2024 was -$2.68M, with a strong operating margin of -887%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Island Pharmaceuticals Limited remained robust at -$1.98M, reflecting operational efficiency. Net income dropped to -$1.71M, with an EPS of -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan